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Background: Asthma is a complex disease presenting with variable symptoms which are sometimes hard to
control. The purpose of the study was to describe the prevalence of asthma symptoms, use of asthma medications
and allergic sensitization in subjects with asthma. We also related those indices to the level of asthma control, lung
function and in particular, cough.
Methods: An extensive questionnaire was sent to randomly selected adults from the West Sweden region. Clinical
examinations and interview were performed in a subset. Of the participants, 744 were defined as having an ongoing
asthma - reported ever having asthma or physician diagnosed asthma and one of the following – use of asthma
medications, recurrent wheeze or attacks of shortness of breath with or without wheeze in the last 12 months.
A respiratory disease-free control group of 847 subjects was also described.
Results: According to GINA guidelines, 40.6% of the asthmatics had partly controlled and 17.8% had uncontrolled asthma.
Asthmatic subjects reported significantly more symptoms in the last 12 months than the control group – wheezing
(79.4 vs 9.2%), shortness of breath (36.1 vs 2.5%), wheezing with shortness of breath (58.7 vs 1.3%). Important
complaints were morning cough (42.5 vs 15.5%), cough with sputum production (36.1 vs 6.8%) and longstanding
cough (32.5 vs 11.1%), which bothered two thirds of the uncontrolled and one third of partly controlled subjects.
Asthma medications were used by 87.5% of the asthmatics, although around 30% of them who had insufficiently
controlled disease used only short-acting beta-agonists. Asthmatics also had lower lung function, reacted to lower
doses of methacholine that the controls and 13.6% of them had a FEV1/FVC ratio below 0.7. Allergic rhinitis was
reported by 73.8% of the asthmatics and they were more frequently sensitized to several common allergens.
Conclusions: Approximately 60% of asthmatics from this population-based study had insufficiently controlled asthma
and persistent complaints, despite a high use of asthma medications. These self-reported symptoms were supported
by clinical examination data. Increased cough frequency is an indicator of a more severe and difficult to control disease
and should be considered when asthma is characterized.
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Asthma is a complex syndrome with variable clinical
course and presentation which is estimated to trouble more
than 300 million people worldwide [1]. An increase in
asthma prevalence and morbidity was noted from the mid-
dle of the last century [2-4] but this tendency seems to have* Correspondence: jan.lotvall@gu.se
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unless otherwise stated.subsided in the last decade, at least in the Westernised
countries. [5-7]. A recent large-scale epidemiological survey
in Sweden revealed an estimated prevalence of asthma
around 8.5% suggesting a steady level for the last two
decades [5].
Asthma is classically characterized by variable episodes
of shortness of breath, chest tightness, wheezing and
cough which can concur or be present at different times.
Complementary lung function tests often show decreased
forced expiratory volume in 1 second (FEV1), increasedral Ltd. This is an Open Access article distributed under the terms of the Creative
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methacholine and reversibility of more than 12% and
200 ml after inhalation of a bronchodilator during periods
with asthma symptoms [8]. Even though breathlessness and
wheeze are more frequent asthma symptoms, cough often
seems to be the most troublesome and problematic com-
plaint for the patient. It also tends to be more resilient to
treatment with bronchodilators than the other complaints
[9]. Cough often presents as a longstanding symptom, even
if the disease is adequately controlled by anti-inflammatory
treatment, and recently it was shown that transient receptor
potential vanilloid 1 channels are overexpressed in the
bronchial epithelium of more severe asthma [10,11]. More-
over, cough might be associated with airway hyperreactivity
without the presence of dyspnea, wheezing and airflow ob-
struction, an entity that has been coined as cough-variant
asthma [12]. Asthma is often accompanied by several co-
morbidities like allergic rhinitis (AR) and chronic rhinosi-
nusitis (CRS) which are also considered to be substantial
risk factors for asthma development [13-16] and the latter a
predictor for more severe disease [17,18]. AR and CRS also
cause dripping of secretions back to the nasopharynx lead-
ing to perpetuation of cough symptoms [19,20]. Today’s
mainstream asthma treatment is guided by the early use of
anti-inflammatory medications and the increased need for
reliever medications is considered an indicator of inad-
equately controlled disease [21]. Guidelines suggest the use
of short-acting beta-2 agonists (SABA) alone should be
given exclusively to a small group of asthmatics with inter-
mittent disease.
The aim of the study was to determine the prevalence of
respiratory symptoms, the use of asthma medications, the
presence of concomitant diseases and the level of asthma
control in the subset of subjects from the West Sweden
Asthma Study with asthma, and to relate these to lung
physiology and cough, with the hypothesis that these are
interconnected. The understanding of such associations is
important to dissect mechanisms of asthma severity.
Methods
Study population, questionnaire and clinical examinations
The grounds for the sample selection were based on a
large scale population study, initiated in 2008 in West
Sweden that is described in details elsewhere [5]. The
sampling procedure is depicted on Figure 1. In short, an
extensive postal questionnaire was sent to 30 000 people,
randomly selected from the West Sweden region, aged
16-75 years, of which 18 087 participated. It comprised
of the OLIN- questionnaire and a Swedish version of the
GA2LEN questionnaire and additionally of questions
about environmental and occupational exposures as well
as family background and socioeconomic status. From
the responders, a randomly selected sample of 2000 sub-
jects as well as all those who reported ever asthma withcurrent symptoms or asthma medication or physician di-
agnosed asthma (n = 1524) were invited to take part in
the subsequent clinical phase of the study. Altogether,
2006 subjects agreed to participate in the clinical part
which was conducted between 2009 and 2012.
The clinical part consisted of a detailed interview about
asthma presence, asthma symptoms and medications, ex-
acerbations, health-care and emergency visits, concurrent
obstructive and non-obstructive pulmonary as well as
extra-pulmonary diseases, smoking and asthma triggers.
Clinical examinations included physical check-up, spirom-
etry before and after a bronchodilator, fractional exhaled
nitrogen oxide (FeNO) measurement, methacholine test-
ing for bronchial hyperresponsiveness, skin-prick tests to
11 common allergens (D. Pteronyssinus, D. farina, Alter-
naria, Cladosporium, German cockroach, dog, cat, horse,
timothy, mugwort, birch) and blood testing. The focus of
the present study was a subset of these subjects (n = 744)
who were defined as having ongoing asthma - reported
ever having asthma or physician diagnosed asthma and
one of the following in the last 12 months – 1) use of
asthma medications, 2) recurrent wheeze or 3) attacks of
shortness of breath with or without wheeze. This is a
slightly more severe group than sometimes described in
epidemiology as “current asthma”, which would include
also individuals with any wheeze in the last year. The re-
ported symptoms and objective measurements were com-
pared with a group of respiratory disease – free (RDF)
subjects (n = 847) – those not having reported ever or
physician diagnosed asthma or asthma symptoms and use
of asthma medications, COPD, chronic bronchitis, emphy-
sema or tuberculosis and chronic productive cough.
The study was approved by the local Ethics Committee
of University of Gothenburg.
Definitions
Definitions are based on the questions from the interview:
Ever asthma:” Have you ever had asthma?”; Physician-
diagnosed asthma:” Have you been diagnosed as having
asthma by a doctor?”; Asthma medications:” Have you
used asthma medications (permanently or as needed) in
the last 12 months?”; Shortness of breath;”Have you ever
had suddenly appearing shortness of breath or breathless-
ness?” and “have you had these symptoms in the last
12 months?”; Recurrent wheeze:” Do you usually have
wheezing or whistling in the chest when breathing?”; Any
wheeze:” Have you had whistling or wheezing in the chest
on any occasion during the last 12 months?”; Wheezing
with shortness of breath: Yes to Any wheeze and”Have you
been at all breathless when the wheezing or whistling was
present?”; Longstanding cough:” Have you had a longstand-
ing cough during the last 12 months?”; Morning cough: “Do
you usually cough or hawk in the mornings?”, Sputum pro-
duction:” Do you usually cough or hawk phlegm from the
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Figure 1 Sampling procedure of defining the asthma and respiratory disease-free control groups.
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is difficult to bring up by coughing and hawking?”; Sputum
production longer than 3 months per year:” Do you cough
of hawk phlegm (or do you have phlegm which is difficult
to bring up despite coughing) most days in periods of at
least 3 months per year?”; Allergic rhinitis:” Do you cur-
rently have or have you ever had allergic nose problems of
hay fever?”; Physician – diagnosed COPD, chronic bron-
chitis, emphysema, tuberculosis:” Have you been diagnosed
as having COPD, chronic bronchitis, emphysema or tuber-
culosis by a physician” (asked in separate questions); Doc-
tor’s office visits:” Have you consulted a physician or other
medical care because of breathlessness, shortness of breath
or whistling in the chest, cough with or without phlegm,
phlegm in the chest or other lung or airway problems in
the last 12 months?”; Hospitalisations: “Have you been hos-
pitalised due to problems with your breathing during the
last 12 months?”; Emergency unit visits:” Have you visited
the emergency unit because of problems with your breath-
ing during the last 12 months?”; Level of asthma control –
controlled, partly controlled and uncontrolled (according to
GINA 2006 guidelines) based on the presence of daytime/
nighttime symptoms, limitation of daily activities, use of re-
liever medications, pulmonary function and exacerbations,
evaluated by the person conducting the interview. With re-
gard to GINA guidelines patients were categorised as hav-
ing controlled asthma when they had no limitation of daily
activities, nocturnal symptoms and exacerbations, had none
or twice or less a week of daytime symptoms and need forrescue medications as well as normal lung function (FEV1
> 80% predicted). Partly controlled were patients having
any of the following – limitation of activities, nocturnal
symptoms/awakenings, more than twice a week had symp-
toms during the day and required reliever medication, had
one or more exacerbation per year and FEV1 below 80%
predicted. All subjects who reported three or more of the
features of partly controlled disease or exacerbation in any
week were regarded as uncontrolled asthmatics.
Analyses
Statistical analyses were performed using IBM SPSS Statis-
tics for Windows, Version 21.0. Armonk, NY: IBM Corp.
Descriptive statistics (frequencies, means and standard de-
viation) were acquired to describe the characteristics of
the subjects. Proportions were compared with chi-square
test and Mantel-Haenszel test for trend was used when-
ever appropriate. Continuous variables were analysed
using unpaired t-test. P-value of <0.05 was regarded as sta-
tistically significant. Adjusted logistic regression analyses
were performed to determine risk factors, presented as
odds ratios (OR) with 95% confidence intervals (95% CI).
Results
General characteristics
The general characteristics of the participants in the study
as well as smoking status and body mass index are pre-
sented in Table 1. The studied populations did not differ
in terms of smoking status. As for BMI there were
Table 1 Age, sex, BMI and smoking status of the asthmatics and the controls
Variables No Current asthma No (%) No Controls No (%) P values
Number of subjects 744 847
Sex (women) 460 (61.8) 451 (53.2) 0.001
Age 47.6 ± 15.5 49.9 ± 15.5 0.002
BMI 743 847
<20 23 (3.1) 38 (4.5) 0.150
20-25 242 (32.6) 337 (39.8) 0.003
25-30 289 (38.9) 364 (43.0) 0.099
≥30 189 (25.4) 108 (12.8) <0.001
Smoking status 742 844
Non-smokers 386 (52) 457 (54.1) 0.206*
Ex-smokers 261 (35.2) 298 (35.3)
Smokers 95 (12.8) 89 (10.5)
Data are presented as No (%), except for age presented as mean ± SD. Chi-square tests are used to make comparisons between individual variables. *p-value from
the test for trend.
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having BMI above 30 (25.4% vs 12.8%, p < 0.001) than con-
trols. Also, the women tend to be more represented in
the asthmatic sample (61.8% vs 53.2% in the RDF con-
trols sample) but this is in accordance with the litera-
ture data about sex difference in asthma prevalence
[22]. Furthermore, risk factor analysis showed that fe-
male gender and BMI > 30 increase the risk of having
uncontrolled asthma (Table 2).
Respiratory symptoms
The respiratory symptoms reported in the last 12 months
were significantly pronounced in the asthmatic group
compared to the RDF group (Table 3). The most prevalent
symptoms were wheezing (79.2% vs 9.2%), wheezing with
shortness of breath (58.7% vs 1.3%) and morning cough
(42.5% vs 15.5%), followed by productive cough (36.1% vsTable 2 Adjusted logistic regression showing risk factors (Od










Significant risk factors are highlighted in bold. Reference categories were: male gender6.8), shortness of breath (36.1% vs 2.5%) and longstanding
cough (32.5% vs 11.1%), all significant at p < 0.001. Add-
itionally, when longstanding or morning cough were eval-
uated in the absence of shortness of breath and wheezing,
asthmatic subjects were significantly less than the RDF con-
trol group (1.9% vs 7.8% and 3.1% vs 11.2%, respectively)
(Figure 2a). This observation accounts for the multilayered
nature of the asthmatic condition and poses question on
the appraisal of a disease presenting only with cough. When
reporting different types of cough, asthmatics have clus-
tered complaints (Figure 2b), and report having productive
cough always coupled with longstanding and/or morning
cough. We also found that productive, morning and long-
standing cough increased the risk of having partly or un-
controlled disease (Table 2). Control subjects, on the other
hand, have less frequent complaints and tend to report
them as separate symptoms, with very few (0.9%) havingds Ratios (95% confidence intervals)) associated with
Partly controlled asthma Uncontrolled asthma
OR (95% CI) OR (95% CI)
1.022 (1.006 – 1.038) 1.037 (1.013 – 1.062)
1.663 (1.118 – 2.475) 2.231 (1.240 – 4.012)
0.799 (0.512 – 1.248) 0.868 (0.467 – 1.613)
1.265 (0.444 – 3.604) 1.040 (0.266 – 4.071)
1.059 (0.675 – 1.660) 1.087 (0.636 – 1.856)
1.206 (0.708 – 2.054) 2.543 (1.455 – 4.447)
2.263 (1.438 – 3.562) 4.182 (2.332 – 7.497)
2.991 (1.888 – 4.738) 6.691 (3.575 – 12.524)
2.075 (1.379 – 3.121) 4.679 (2.635 – 8.311)
, BMI 20-25, having no longstanding, productive and morning cough, respectively.
Table 3 Prevalence of respiratory symptoms reported in the last 12 months in the groups of the asthmatics and controls
Variables No Current asthma No (%) No Controls No (%) P values
Symptoms 744 847
Longstanding cough 242 (32.5) 94 (11.1) <0.001
Morning cough 316 (42.5) 131 (15.5) <0.001
Sputum production 268 (36.1) 57 (6.8) <0.001
Wheezing 591 (79.4) 78 (9.2) <0.001
Wheezing with shortness of breath 437 (58.7) 11 (1.3) <0.001
Shortness of breath 269 (36.1) 21 (2.5) <0.001
Longstanding cough without other symptoms 14 (1.9) 66 (7.8) <0.001
Morning cough without other symptoms 23 (3.1) 95 (11.2) <0.001
Allergic rhinitis and longstanding cough 170 (22.8) 34 (4.0) <0.001
Allergic rhinitis 548 (73.8) 259 (30.7) <0.001
Data are presented as No (%). Chi-square tests are used to make comparisons between individual variables.
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at the same time.
Allergic rhinitis is reported in 73.8% of the asthmatic
subjects, compared to 30.7% of the RDF control group,
and allergic rhinitis and cough are present in 22.8% of
the asthmatics but in only 4% of the controls.
Lung function and sensitisation
The results from the pulmonary function tests, skin-prick
tests and health-care visits are summarised in Table 4. The
mean value of pre-bronchodilator FEV1% predicted in the
asthmatics is 90.6 ± 17.6 (standard deviation) versus 101 ±
12.9 in the control group (Figure 3). Increase of the FEV1
with ≥ 12% and 200 ml after inhalation of a bronchodilator
was noted in 24.8% of the asthmatics and 3.4% in the RDF
controls. Low lung function, estimated as having FEV1
below 80% predicted, was present in 23.2% in the asthma
group, but only is 5.3% in the respiratory disease-free
group. Proportion of asthmatics that react with decrease
of the FEV1 more than 20% after inhaling a cumulative
dose of 1.96 mg of methacholine is 70.9%, but still 32% of
the control group also shows increased reactiveness of
their airways (Figure 4).
Subjects with asthma that had at least one positive skin-
prick test were 71.8% of those who had the test performed
(575 subjects) and 33.1% of the controls showed positive
results (from 577 subjects tested). Moreover, when sensi-
tisation was present in the asthmatics it was often to four
or more allergens highlighting a noticeable polysensitisa-
tion in comparison to the respiratory disease-free subjects
(Figure 5).
Health–care visits and co-morbidities
Over a period of one year, 35.3% of the asthmatics re-
ported to have sought medical services for respiratory
symptoms, 2.2% were hospitalised and 10.6% reported
emergency care visits, while the corresponding percentagein the RDF control group was 9.5%, 0.1% and 1.3%
respectively.
The studied asthmatic population also outlined for the
presence of respiratory comorbidities, characterised by the
use of asthma medications and the level of asthma control
that the subjects have maintained for the last 12 months
(Table 5). Physician diagnosed chronic bronchitis was
present in 11.3% of the asthma group, chronic obstructive
pulmonary disease was reported by 5.8% and emphysema
by 0.7%.
Medications and asthma control
From the asthmatics, 87.5% reported using some type of
asthma medication (Figure 6). Inhaled corticosteroids
(ICS) used alone or in combination with SABA and/or
LABA, represented 60.2% of the utilised medications.
SABAs as a sole treatment modality were used by 27.2%
of the asthmatics. In respect to the level of asthma control,
subjects were designated as having controlled, partly con-
trolled or uncontrolled disease according to Global Initia-
tive for Asthma (GINA) 2006 criteria. 41.6% of the
asthmatics had controlled disease, still 40.6% were partly
controlled and 17.8% of an uncontrolled asthma. We also
evaluated how frequent different types of cough were
present in the asthmatic subjects who were stratified on
the level of control (Table 6). Morning cough was present
in the 46% of the partly controlled and 68.1% in the un-
controlled subjects, productive cough – in 38.2% and
68.1% in these groups, respectively and longstanding
cough in 33.1% of the partly and 55.5% of the uncontrolled
asthmatics.
Discussion
The West Sweden Asthma Study provides one of the most
current descriptions of the state of respiratory symptoms
and asthma at a population level in northern Europe [5].








Figure 2 A Prevalence of cough, shortness of breath and wheezing in asthma (n = 744) and respiratory disease-free control group
(n = 847), B Prevalence of cough complaints in asthmatics (n = 744) and respiratory disease - free control group (n = 847).
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Table 4 Description of lung function, sensitisation and health-care utilisation
Variables No Current asthma No Controls P values
Overall number of subjects 744 847
FEV1% predicted 707 90.6 ± 17.6 816 101.0 ± 12.9 <0.001
FEV1% predicted below 80% 707 164 (23.2) 816 43 (5.3) <0.001
Positive reversibility after a bronchodilator 444 110 (24.8) 465 16 (3.4) <0.001
FEV1/FVC ratio < 0.7 705 96 (13.6) 817 33 (4.0) <0.001
FeNO ppb# 597 26.88 ± 24.3 676 19.03 ± 11.0 <0.001
Reactiveness to PD20≤ 1.96 mg** 275 195 (70.9) 328 105 (32.0) <0.001
At least 1 positive SPT 575 413 (71.8) 577 191 (33.1) <0.001
Number of positive SPT in the sensitised subjects 413 191
1 79 (19.1) 68 (35.6) <0.001*
2 63 (15.3) 54 (28.3)
3 75 (18.2) 29 (15.2)
≥4 196 (47.4) 40 (20.9)
Doctor's office visits 740 263 (35.3) 844 80 (9.5) <0.001
Hospitalisations 735 16 (2.2) 844 1 (0.1) <0.001
Emergency visits due to respiratory problems 733 78 (10.6) 842 11 (1.3) <0.001
Comparisons of FEV1/FVC ratio, PD20 reactiveness, positive reversibility after a bronchodilator and BMI are done using Chi-square test, other clinical parameters
are compared using unpaired t-test. *p-value from the test for trend.
#measured at 50 ml/s.
**% of subjects reacted to methacholine dose ≤ of 1.96 mg with 20% fall in the FEV1.
Data are presented as number of subjects No (%) or mean ± SD.
Figure 3 Difference in FEV1% predicted between current asthmatics and RDF controls. Asthmatics have distinctly lower lung parameters than
the control group.
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Figure 4 Fraction of current asthmatics and respiratory disease-free controls who have not reacted to cut-off values for positive
methacholine reactivity.
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self-administered questionnaires, with objective data from
clinical examinations. This representative cohort of asth-
matics had lower lung function than respiratory disease-
free subjects, but on average the loss of lung function was
small [23]. Nevertheless, around 13% of the asthmatics
had persistent airflow limitation and post – bronchodilator
FEV1/FVC ratio below 0.70. In some of these subjects this
could be due to overlapping COPD, while in others it might
be due to variable obstruction without a well-defined cause
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Figure 5 Prevalence of the sensitisation to a number of common alle
Asthmatics have more pronounced sensitisation to polyallergens.increased airway responsiveness, also 30 percent of the re-
spiratory disease-free subjects responded to methacholine.
It is well known that airway hyperresponsiveness can be
observed also in non-asthmatics, including individuals
with allergic rhinitis and atopy [25-27], and in smokers
[28,29], but can also be a predictor for future development
of asthma. In the respiratory disease-free subjects, 45% of
those who reacted positively to methacholine challenge re-
ported allergic rhinitis and 15% were current smokers
which could to some extend account for the increased air-
way responsiveness. In regard to allergic sensitisation, theRDF Control group
1 No positive
rgens in current asthmatics (n = 575) and RDF controls (n = 577).
Table 5 Prevalence of comorbidities, use of asthma
medications and the level of asthma control (according
to GINA guidelines) in the asthmatic population
Variables No Prevalence No (%)
Physician diagnosed comorbidities 744
COPD 43 (5.8)
Chronic bronchitis 84 (11.3)
Emphysema 5 (0.7)
Level of control (GINA 2006) 669
Controlled 278 (41.6)
Partly controlled 272 (40.6)
Uncontrolled 119 (17.8)
Exacerbations≥ 1 744 151 (20.3)
Asthma medications 744 651 (87.5)












Prevalence in the groups%
Longstanding cough 18.0 33.1 55.5




Morning cough 25.9 46.0 68.1
Half of the uncontrolled and one third of partly controlled subjects are
troubled by different types of cough.
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prick reaction to at least one allergen compared to one
third of the tested control subjects. Also, asthmatics were
far more frequently sensitised to more than four allergens,
results which are consistent with previous studies on
asthma with different level of severity [17,30]. In the group
of asthmatics, individuals with obesity were significantly
more than the individuals in the control group which is in
accordance with the bidirectional link which has been
speculated between asthma and obesity [31,32].
A considerable proportion of the subjects from the asth-
matic sample were troubled by respiratory symptoms in the
year preceding their examination, with the most frequent
ones being wheezing with or without shortness of breath,
morning and productive cough, shortness of breath and
longstanding cough. Furthermore, many asthmatics pre-
sented with symptoms that were overlapping, supporting





ICS (alone or 
combination)
Figure 6 Proportions of different asthma medications used in
the last 12 months. 87.5% of the asthmatics used some type of
asthma medication. SABA – Short acting beta-agonist, ICS –
inhaled corticosteroids which includes only ICS, ICS + SABA, ICS and
LABA (separately or in a fixed combination), only fixed combination,
fixed combination and SABA, Others – only LABA, anticholinergics,
antileukotrienes, oral steroids, theophylline and different combinations
between them.syndrome [33]. We also focused our analyses on different
types of cough and their relation with other symptoms and
level of asthma control. The asthmatics reported having
productive cough always in the presence of longstanding
or morning cough and these complaints were broadly
superimposed upon each other as well as on wheezing and
shortness of breath. By contrast, the control individuals,
apart from reporting cough much less frequently, often re-
ported different cough types separately, resulting in morn-
ing and longstanding cough without other respiratory
symptoms being more frequent in the control group than
in the group of the asthmatics. It can only be speculated
that some of the latter subjects might fall into the group
of cough-variant asthma, but the cross-sectional design of
the study precludes us from making such conclusions
[34]. Moreover, when we examined the risk factors for
partly and uncontrolled disease we found that productive,
longstanding and morning cough were highly significant
contributors to unsatisfactory controlled disease in the
asthmatic group.
Subjects from the asthma group were also classified as
having controlled, partly controlled or uncontrolled asthma
according to GINA guidelines. Accordingly, around 60% of
the asthmatics had inadequately controlled disease and 20%
had one or more exacerbations in the last year. The preva-
lence of longstanding, morning and productive cough in-
creased with the decline of the level of control so that
ultimately around 70% of the uncontrolled asthmatics
were troubled by morning and productive cough and 55%
by longstanding cough. It has been recently proposed that
cough frequency can be used as a surrogate marker of
asthma control and that “'uncontrolled' asthma patients
have significantly higher cough rates than those 'partly
controlled' or 'controlled'” [35], a notion that is reinforced
by our results. However, further case-control longitudinal
studies controlling for co – morbidities are required to
support this conjecture.
In our study sample, 87.5% of the asthmatics utilised
some type of asthma medication during the last 12 months.
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timely and adequate use of inhaled corticosteroids solely
or in combination with bronchodilators. Sixty percent of
the asthmatic subjects that we studied were indeed report-
ing use of some form of ICS, results that correspond to
the data from the general population [36]. Asthma manage-
ment guidelines recommend the use of SABAs to relieve
bronchospasm during acute exacerbation and prevent exer-
cise – induced bronchospasm and they should only be used
on “as – needed” basis and in the minimal required dose
[8]. However, our results show that nearly 30 percent of the
asthmatics used solely inhaled short-acting beta - agonist
which comprised of around 15% of the uncontrolled and
20% of the partly controlled asthmatics. These results put
stress on the necessity of closer monitoring of asthma
medication regimens and compliance.
In the present study we opted for more stringent inclu-
sion criteria of the asthmatic individuals with ongoing
asthma focusing on those who reported “recurrent
wheeze” and not only “any wheeze” in the last 12 months,
which can be considered more rigorous than other epi-
demiological studies evaluating “current asthma” [37-39].
Our approach therefore most likely comprises a slightly
more severe group of asthmatics. Additionally, it is also
possible that individuals with perhaps more severe and
less controlled disease are more prone to attend to the
clinical investigation, which could results in an overrepre-
sentation of this group. However, any such effect on
prevalence may not be extensive, since our data is in ac-
cordance with previous studies from Europe [40,41]. A
cross-sectional study like ours provide important informa-
tion about present asthma prevalence and how symptoms
and other factors overlap, but follow up studies will give
more information about time trends and current risk fac-
tors of disease progress.
In conclusion, the results from the present study pro-
vide the most up-to-date report on asthma symptoms in
Northern Europe, and specifically how traditional
asthma symptoms and cough overlap. Importantly,
approximately 60% of the asthmatics have insufficient
control of their disease according to GINA criteria,
which may correspond to inadequate utilisation of
asthma medications as well as difficult to treat disease.
Importantly, cough is relatively more common among
asthmatics with signs of more severe disease and should
be thoroughly considered when phenotypes of asthma
are characterised.
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